- Nebulized, single, intermittent
- 500 mcg every 20 minutes PRN X 3 doses with the single dose nebulized albuterol treatment
- Nebulized, continuous
- 1500 mcg/hour X 1 hour with the 1-hour continuous albuterol treatment
We concur with the (GINA, 2018) guideline and recommend IB be used in conjunction with albuterol and corticosteroids in patients with severe asthma exacerbations, or exacerbations that do not respond to initial therapy. This recommendation is based on high quality evidence that the addition of IB decreases hospital admissions in the population (OR = 0.6, 95% CI [0.45, 0.60]), and moderate quality evidence that the change from baseline forced expiratory volume in 1 second, percent predicted (FEV1, % predicted) at 60 minutes past the IB treatment is greater (Mean difference = 10.08, 95% CI [6.25, 13.92].
For additional information click here for the Ipratopium Critically Appraised Topic (CAT)
GINA. (2018). Global Strategy of Asthma Management and Prevention.